Teva Pharmaceutical Industries Limited
36.85USD
+0.0900 (+0.24%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,142 | 3,982 | 1,500 | 4,480 | 4,176 | 3,891 | 4,229 | 4,332 |
| Cost of Revenue | 1,989 | 2,011 | 2,056 | 2,176 | 2,074 | 2,014 | 2,109 | 2,183 |
| Gross Profit | 2,153 | 1,972 | 2,656 | 2,304 | 2,102 | 1,877 | 2,121 | 2,148 |
| Operating Income | -231 | 652 | 300 | 882 | 455 | 519 | -29 | -51 |
| Net Income | -576 | 369 | 480 | 433 | 282 | 214 | -217 | -437 |
| EPS (Diluted) | $-0.49 | $0.31 | $0.41 | $0.37 | $0.24 | $0.18 | $-0.19 | $-0.39 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)